Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 13, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how well two treatments, pembrolizumab and nivolumab, work for patients with a type of lymphoma called Primary Mediastinal B Cell Lymphoma (PMBCL) that has come back or has not responded to previous treatments. The study will review real-life cases of patients aged 18 and older who received these medications. Specifically, it will focus on those who received pembrolizumab alone or nivolumab along with another medication called brentuximab vedotin. The goal is to understand how effective and safe these treatments are in everyday clinical practice.

To be eligible for this trial, patients must have a confirmed diagnosis of relapsed or refractory PMBCL and have received one of the studied treatments by November 2021. They should also be at least 18 years old and provide written consent if needed. Participants in the trial can expect their experiences to be reviewed, helping researchers gather important information on how these therapies perform outside of controlled clinical trials. This study is currently recruiting participants, which means they are looking for individuals who meet the criteria to take part in this important research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed diagnosis of Primary Mediastinal B Cell Lymphoma Relapsed/Refractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a real-life context with till Novembre 2021
• • 2. Age ≥ 18 years at enrollment
• • 3. Signature of written informed consent (where applicable)
• Exclusion Criteria:
• • 1. Primary Mediastinal B Cell Lymphoma Relapsed/Refractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a clinical trial context.